Genbank References: capsid (p24)

Authors	Title	Citation	E-value	# in Gb	#Pts	ART	Source	Cloning	StudyType
deCamp (2018)	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120	PLoS ONE 12 (11), e0185959 (2017)	3.27e-158	468	47	Naive	Plasma	Direct PCR; SGS	Molecular epidemiology

Download sequences

Accession	IsolateName	Country	Coll Date	Clone	MolType	Source	Note	FirstAA	LastAA	MutList
MG196652	505_0012a.LH01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196651	505_0012a.LH02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196649	505_0012a.LH04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196648	505_0012a.LH05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196643	505_0012a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196647	505_0012a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196642	505_0012a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196645	505_0012a.WG04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196646	505_0012a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196644	505_0012a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 12057;participant 505-0012;subtype: B	1	231	6L,71D,83L,87Q,91V,120H,128D,148S,154K,170R,180D,194S,210S
MG196658	505_0049a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196654	505_0049a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196661	505_0049a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196656	505_0049a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	4*Q,6A,27I,31AV,83L,87Q,92P,120H,128D,136M,148V,180D
MG196662	505_0049a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196657	505_0049a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,82GR,83L,87Q,92P,120H,128D,136M,148V,180D
MG196653	505_0049a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196655	505_0049a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196659	505_0049a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196660	505_0049a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 880505;participant 505-0049;subtype: B	1	231	6A,27I,83L,87Q,92P,120H,128D,136M,148V,180D
MG196667	505_0071a.WG01	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196666	505_0071a.WG02	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196668	505_0071a.WG03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196672	505_0071a.WG04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196664	505_0071a.WG05	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196665	505_0071a.WG06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196663	505_0071a.WG07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196670	505_0071a.WG08	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196671	505_0071a.WG09	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196669	505_0071a.WG10	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1738;participant 505-0071;subtype: B	1	231	6L,41T,83L,91V,128D,148A,154K,180D,200L,204S,208G
MG196675	505_0090a.LH1	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196674	505_0090a.LH17	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196677	505_0090a.LH18	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196678	505_0090a.LH6	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196673	505_0090a.LH7	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196676	505_0090a.LH9	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 1359;participant 505-0090;subtype: B	1	231	6N,12Y,14S,15L,44A,78V,83L,86Q,87Q,91V,96I,116A,120S,124V,136M,180D,183Q,205M,208G
MG196689	505_0102a.WG01	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,14S,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196690	505_0102a.WG02	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,14S,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196695	505_0102a.WG03	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,92AV,96I,98D,116A,120S,124V,148V,154K,180D
MG196692	505_0102a.WG04	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,14S,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196693	505_0102a.WG05	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196691	505_0102a.WG07	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,14S,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196696	505_0102a.WG08	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196698	505_0102a.WG09	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196694	505_0102a.WG10	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196697	505_0102a.WG11	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 1186;participant 505-0102;subtype: B	1	231	6L,15L,27I,41T,83M,86A,87Q,91V,96I,98D,116A,120S,124V,148V,154K,180D
MG196706	505_0122a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196709	505_0122a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196703	505_0122a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196707	505_0122a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196699	505_0122a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K,190~,229K
MG196702	505_0122a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,12HR,83L,116A,128D,132G,154K
MG196708	505_0122a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196700	505_0122a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196701	505_0122a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196710	505_0122a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196705	505_0122a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196704	505_0122a.WG12	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 5417;participant 505-0122;subtype: B	1	231	4R,6L,83L,116A,128D,132G,154K
MG196712	505_0280a.WG01	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196715	505_0280a.WG02	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196719	505_0280a.WG03	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196711	505_0280a.WG04	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196716	505_0280a.WG05	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196720	505_0280a.WG06	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196714	505_0280a.WG07	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196718	505_0280a.WG08	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196713	505_0280a.WG09	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196717	505_0280a.WG10	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 1299362;participant 505-0280;subtype: B	1	231	6L,14S,44A,72V,83T,91V,115V,116A,124V,148V,154K,178T,180D
MG196730	505_0332a.LH1	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196726	505_0332a.LH10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196724	505_0332a.LH13	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196727	505_0332a.LH14	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196721	505_0332a.LH2	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196725	505_0332a.LH3	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196728	505_0332a.LH4	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196731	505_0332a.LH5	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196723	505_0332a.LH6	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196729	505_0332a.LH8	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196722	505_0332a.LH9	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3599;participant 505-0332;subtype: B	1	231	6M,14P,83L,86A,87Q,91V,96V,116A,120H,148I,180D,225S
MG196754	505_0390a.WG02	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196751	505_0390a.WG04	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196750	505_0390a.WG05	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196753	505_0390a.WG06	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196747	505_0390a.WG07	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196749	505_0390a.WG08	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196752	505_0390a.WG09	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196748	505_0390a.WG10	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196745	505_0390a.WG12	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196746	505_0390a.WG14	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 2717600;participant 505-0390;subtype: B	1	231	6M,15L,79D,91V,107V,120S,132K,136M
MG196763	505_0396a.WG1	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196757	505_0396a.WG10	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196755	505_0396a.WG14	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196764	505_0396a.WG15	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196760	505_0396a.WG4	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225GS,230I
MG196761	505_0396a.WG5	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196762	505_0396a.WG6	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196759	505_0396a.WG7	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,31AD,44A,83L,180D,208G,225S,230I
MG196758	505_0396a.WG8	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196756	505_0396a.WG9	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 23217;participant 505-0396;subtype: B	1	231	6L,14P,44A,83L,180D,208G,225S,230I
MG196773	505_0645a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196765	505_0645a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196770	505_0645a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196771	505_0645a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,19A,83L,136M,194S
MG196774	505_0645a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196772	505_0645a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196766	505_0645a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S,197DG
MG196769	505_0645a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196767	505_0645a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196768	505_0645a.WG13	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 1705177;participant 505-0645;subtype: B	1	231	6L,83L,136M,194S
MG196775	505_0686a.WG01	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225GS
MG196781	505_0686a.WG02	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196784	505_0686a.WG03	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196785	505_0686a.WG05	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196780	505_0686a.WG06	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196776	505_0686a.WG07	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196786	505_0686a.WG08	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196782	505_0686a.WG09	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196779	505_0686a.WG10	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196777	505_0686a.WG13	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196783	505_0686a.WG14	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 73564;participant 505-0686;subtype: B	1	231	6L,27I,83L,128D,136M,154K,178T,225S
MG196792	505_0695a.WG01	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196791	505_0695a.WG02	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196789	505_0695a.WG03	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196794	505_0695a.WG05	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196787	505_0695a.WG06	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196788	505_0695a.WG07	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196795	505_0695a.WG08	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196793	505_0695a.WG09	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196796	505_0695a.WG10	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196790	505_0695a.WG11	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 22988;participant 505-0695;subtype: B	1	231	6L,15L,27I,41T,83L,96L,110N,116A,120H,148V,154K,178T
MG196802	505_0724a.LH01	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196799	505_0724a.LH02	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196803	505_0724a.LH03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196801	505_0724a.LH04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196800	505_0724a.LH05	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196813	505_0724a.LH06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196804	505_0724a.LH07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196812	505_0724a.LH08	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196797	505_0724a.WG01	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196815	505_0724a.WG02	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196798	505_0724a.WG03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 23319;participant 505-0724;subtype: B	1	231	6L,11I,14P,50G,59I,83L,91V,111T,116A,120G,123A,128D,154K,178T,199R,200S,205M,208G
MG196819	505_0772a.WG2	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,187D,208G,225A
MG196816	505_0772a.WG3	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,187D,208G,225A
MG196817	505_0772a.WG4	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,169CY,187D,208G,225A
MG196820	505_0772a.WG5	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,187D,208G,225A
MG196818	505_0772a.WG6	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,187D,208G,225A
MG196821	505_0772a.WG7	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 38735;participant 505-0772;subtype: B	1	231	41T,83L,86P,87Q,96I,116T,120S,148A,187D,208G,225A
MG196826	505_0821a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196827	505_0821a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196823	505_0821a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196824	505_0821a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196831	505_0821a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,29EG,91V,178T
MG196829	505_0821a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196828	505_0821a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196830	505_0821a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196822	505_0821a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196825	505_0821a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 3302227;participant 505-0821;subtype: B	1	231	6L,91V,178T
MG196845	505_0840a.WG01	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196840	505_0840a.WG03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196841	505_0840a.WG04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196844	505_0840a.WG05	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196837	505_0840a.WG06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196843	505_0840a.WG07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196836	505_0840a.WG09	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196839	505_0840a.WG10	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196842	505_0840a.WG11	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 4088319;participant 505-0840;subtype: B	1	231	83L,86A,87Q,96I,98D,116R,128D,194S,230I
MG196852	505_0896a.WG03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196855	505_0896a.WG04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L,174T
MG196851	505_0896a.WG05	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196850	505_0896a.WG06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196853	505_0896a.WG07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196846	505_0896a.WG08	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196854	505_0896a.WG09	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196847	505_0896a.WG12	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196849	505_0896a.WG14	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,83L
MG196848	505_0896a.WG15	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 849022;participant 505-0896;subtype: B	1	231	6L,48H,83L
MG196856	505_0933a.LH1	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196857	505_0933a.LH10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196858	505_0933a.LH13	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196859	505_0933a.LH15	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196860	505_0933a.LH20	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196861	505_0933a.LH23	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196862	505_0933a.LH24	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196863	505_0933a.LH25	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196864	505_0933a.LH4	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196865	505_0933a.LH9	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 610;participant 505-0933;subtype: B	1	231	6M,83L,148S,154K,170R,194S,225A
MG196878	505_0997a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196882	505_0997a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196879	505_0997a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196883	505_0997a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196886	505_0997a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,176QR,230I
MG196881	505_0997a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196887	505_0997a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196888	505_0997a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196885	505_0997a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196880	505_0997a.WG12	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196877	505_0997a.WG13	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196884	505_0997a.WG14	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196889	505_0997a.WG15	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 8803;participant 505-0997;subtype: B	1	231	6G,27I,83L,86A,120G,148V,230I
MG196897	505_0998a.LH12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196896	505_0998a.LH15	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196893	505_0998a.LH16	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196891	505_0998a.LH18	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196894	505_0998a.LH21	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196895	505_0998a.LH22	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,11I,83L,115V,120S
MG196892	505_0998a.LH28	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196900	505_0998a.LH32	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196899	505_0998a.LH33	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196890	505_0998a.LH6	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196898	505_0998a.LH8	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196901	505_0998a.LH9	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 20941;participant 505-0998;subtype: B	1	231	6L,83L,115V,120S
MG196919	505_1012a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196913	505_1012a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196914	505_1012a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196917	505_1012a.WG04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196915	505_1012a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196918	505_1012a.WG07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196921	505_1012a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,36I,83L,180D,225C
MG196912	505_1012a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196916	505_1012a.WG16	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196920	505_1012a.WG17	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 153472;participant 505-1012;subtype: B	1	231	6L,83L,180D,225C
MG196926	505_1144a.LH01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,127E,154K,170R,194S,208G,210S
MG196925	505_1144a.LH02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196928	505_1144a.LH03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196927	505_1144a.LH04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196929	505_1144a.LH05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196930	505_1144a.LH06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196924	505_1144a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196922	505_1144a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,146NS,154K,170R,194S,208G,210S
MG196923	505_1144a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 8584;participant 505-1144;subtype: B	1	231	6L,14P,44A,83L,116A,154K,170R,194S,208G,210S
MG196944	505_1174a.WG01	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196949	505_1174a.WG02	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196946	505_1174a.WG03	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196950	505_1174a.WG04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196951	505_1174a.WG05	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196942	505_1174a.WG06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196945	505_1174a.WG07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D,201IV
MG196947	505_1174a.WG08	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196943	505_1174a.WG09	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196948	505_1174a.WG10	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 7374746;participant 505-1174;subtype: B	1	231	6L,14P,15L,41T,83T,87Q,91V,96I,116A,120H,154K,180D
MG196954	505_1226a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196953	505_1226a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196955	505_1226a.WG04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196958	505_1226a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196961	505_1226a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196962	505_1226a.WG07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196952	505_1226a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196957	505_1226a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196956	505_1226a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196959	505_1226a.WG11	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196960	505_1226a.WG12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 79731;participant 505-1226;subtype: B	1	231	6L,54S,58A,61S,83L,87Q,91V,98D,120S,126I,148V,154K,162K,183G,207Q,208G
MG196969	505_1270a.WG02	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196970	505_1270a.WG04	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196966	505_1270a.WG07	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,121T,148V,154K,178T,183S,225S
MG196967	505_1270a.WG08	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196971	505_1270a.WG09	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196968	505_1270a.WG10	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196964	505_1270a.WG12	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196965	505_1270a.WG13	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196963	505_1270a.WG14	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196972	505_1270a.WG15	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 47360;participant 505-1270;subtype: B	1	231	6H,27I,78V,83L,91V,116A,148V,154K,178T,183S,225S
MG196976	505_1276a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,9*,27I,83L,148V,178T,200AT
MG196981	505_1276a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196979	505_1276a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196980	505_1276a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196982	505_1276a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196978	505_1276a.WG07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196974	505_1276a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196975	505_1276a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196973	505_1276a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196977	505_1276a.WG11	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 1561400;participant 505-1276;subtype: B	1	231	6L,27I,83L,148V,178T
MG196991	505_1278b.LH01	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196984	505_1278b.LH02	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,25KR,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196987	505_1278b.LH03	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,112P,116A,120S,124V,148V,154K,183G,208G
MG196990	505_1278b.LH04	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196995	505_1278b.LH05	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196986	505_1278b.LH06	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,109~,112P,116A,120S,124V,148V,154K,183G,208G
MG196992	505_1278b.LH07	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196988	505_1278b.LH08	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196993	505_1278b.LH09	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196983	505_1278b.LH10	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,116A,120S,124V,148V,154K,183G,208G
MG196996	505_1278b.LH11	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196989	505_1278b.LH12	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196994	505_1278b.LH13	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,208G
MG196985	505_1278b.LH14	USA	2010		genomic RNA	plasma	treatment = vaccine; viral-load = 2919;participant 505-1278;subtype: B	1	231	6L,15L,27I,41T,83I,86P,87Q,96I,110N,116A,120S,124V,148V,154K,183G,199KR,208G
MG197018	505_1295a.WG1	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197013	505_1295a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197019	505_1295a.WG11	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197017	505_1295a.WG3	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,141IV,148V,170R,180D,225S
MG197016	505_1295a.WG4	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197021	505_1295a.WG5	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197022	505_1295a.WG6	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197020	505_1295a.WG7	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197014	505_1295a.WG8	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,183DN,225S
MG197015	505_1295a.WG9	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 57691;participant 505-1295;subtype: B	1	231	6A,11I,27I,41T,44A,50H,68I,83L,91V,96V,120S,135V,148V,170R,180D,225S
MG197027	505_1358a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197025	505_1358a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197030	505_1358a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197029	505_1358a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197026	505_1358a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197031	505_1358a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197023	505_1358a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197028	505_1358a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197024	505_1358a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197032	505_1358a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 505241;participant 505-1358;subtype: B	1	231	6M,14P,15L,16T,27I,31N,41A,83L,116A,132K,136M,154K,216S
MG197039	505_1371a.WG02	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197040	505_1371a.WG03	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197036	505_1371a.WG04	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197037	505_1371a.WG05	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,153M,177C,178T,180D,194S,225S,230I
MG197041	505_1371a.WG06	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197034	505_1371a.WG08	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197033	505_1371a.WG09	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197035	505_1371a.WG10	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197038	505_1371a.WG11	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197042	505_1371a.WG12	USA	2013		genomic RNA	plasma	treatment = vaccine; viral-load = 793126;participant 505-1371;subtype: B	1	231	6L,15L,27I,83L,148V,177C,178T,180D,194S,225S,230I
MG197050	505_1413a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197052	505_1413a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197047	505_1413a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197051	505_1413a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197046	505_1413a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197043	505_1413a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197049	505_1413a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197045	505_1413a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197044	505_1413a.WG10	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197048	505_1413a.WG13	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197053	505_1413a.WG15	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 29502;participant 505-1413;subtype: B	1	231	6L,27I,44A,83L,91V,116A,120G,123A,148V,154K,208G,213D,225S
MG197057	505_1569a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,96I,116T,120S,154K,180D,210S,225S
MG197062	505_1569a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,96I,116T,120S,148V,154K,178T,216S
MG197056	505_1569a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,95*Q,96I,116T,120S,154K,180D,210S,225S
MG197054	505_1569a.WG04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,116A,120G,124V,148V,154K,178T,216S
MG197061	505_1569a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,116A,120G,124V,148V,154K,178T,216S
MG197063	505_1569a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,96I,116T,120S,148V,154K,178T,216S
MG197058	505_1569a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,96I,116T,120S,154K,180D,210S,225S
MG197060	505_1569a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,116A,120G,124V,148V,154K,178T,216S
MG197059	505_1569a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,116A,120G,124V,148V,154K,178T,216S
MG197055	505_1569a.WG11	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 951697;participant 505-1569;subtype: B	1	231	6L,27I,41T,83L,87Q,96I,116T,120S,154K,180D,210S,225S
MG197070	505_1672a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197073	505_1672a.WG12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,50G,54L,59I,83L,91V,116A,120S,128D,154K,178T,225S
MG197067	505_1672a.WG13	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197069	505_1672a.WG14	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197068	505_1672a.WG15	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197066	505_1672a.WG16	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197071	505_1672a.WG18	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197072	505_1672a.WG19	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,50G,54L,59I,83L,91V,116A,120S,128D,154K,178T,225S
MG197064	505_1672a.WG7	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197065	505_1672a.WG8	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 49469;participant 505-1672;subtype: B	1	231	6M,27I,50G,54L,83L,87Q,91V,116A,120S,128D,154K,178T,225S
MG197078	505_1677a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197076	505_1677a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197079	505_1677a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197080	505_1677a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197077	505_1677a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197082	505_1677a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197074	505_1677a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197081	505_1677a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197075	505_1677a.WG12	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 26932;participant 505-1677;subtype: B	1	231	6V,15L,50S,83L,91F,116A,128D,136M,154K,194S,208G,210S,225S
MG197088	505_1730a.WG01	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S,154K
MG197089	505_1730a.WG02	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S,154K
MG197091	505_1730a.WG03	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,58AT,84N,87R,96I,116T,120S
MG197087	505_1730a.WG04	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,7*Q,15L,50T,84N,87R,96I,116T,120S
MG197093	505_1730a.WG05	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	4*,6M,15L,50T,84DN,87R,96I,116T,120S
MG197090	505_1730a.WG06	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S,154K
MG197085	505_1730a.WG07	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S
MG197084	505_1730a.WG08	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S
MG197092	505_1730a.WG09	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,30R,50T,84N,87R,96I,116T,120S
MG197094	505_1730a.WG10	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S
MG197086	505_1730a.WG11	USA	2011		genomic RNA	plasma	treatment = placebo; viral-load = 139203;participant 505-1730;subtype: B	1	231	6M,15L,50T,84N,87R,96I,116T,120S
MG197102	505_1763a.LH01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197099	505_1763a.LH02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,30M,83L
MG197095	505_1763a.LH03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197100	505_1763a.LH04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L,163G
MG197096	505_1763a.LH05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L,167QR
MG197097	505_1763a.LH06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197103	505_1763a.LH07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197101	505_1763a.LH09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197104	505_1763a.LH10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197098	505_1763a.LH12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 507759;participant 505-1763;subtype: B	1	231	6L,83L
MG197120	505_1931a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,183G,194S,208G
MG197116	505_1931a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,183G,208G
MG197119	505_1931a.WG03	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,15L,27I,41T,83L,91A,92P,120S,148V,154K,178T,194S,208G
MG197118	505_1931a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,15L,27I,41T,83L,91A,92P,120S,148V,154K,178T,194S,208G
MG197123	505_1931a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,15L,27I,41T,83L,91A,92P,120S,148V,154K,178T,194S,208G
MG197121	505_1931a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,183G,208G,217V
MG197122	505_1931a.WG08	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,178T,194S,208G
MG197117	505_1931a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,15L,27I,41T,83L,91A,92P,120S,148V,154K,178T,194S,208G
MG197125	505_1931a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,183G,194S,208G
MG197115	505_1931a.WG14	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,15L,27I,41T,83L,91A,92P,120S,148V,154K,178T,194S,208G
MG197124	505_1931a.WG15	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 172240;participant 505-1931;subtype: B	1	231	6L,14S,15L,27I,41T,83L,92P,120S,124V,148V,154K,183G,194S,208G
MG197130	505_1958a.WG01	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,137R,148S,154K,210S,225S
MG197128	505_1958a.WG02	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197133	505_1958a.WG03	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197129	505_1958a.WG05	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197135	505_1958a.WG06	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197126	505_1958a.WG07	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197132	505_1958a.WG08	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197127	505_1958a.WG09	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197131	505_1958a.WG10	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,148S,154K,210S,225S
MG197134	505_1958a.WG11	USA	2013		genomic RNA	plasma	treatment = placebo; viral-load = 177290;participant 505-1958;subtype: B	1	231	6L,10S,15M,27I,83L,86A,87Q,91V,96I,107S,116A,120H,136M,145CY,148S,154K,210S,225S
MG197136	505_1962a.WG03	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197137	505_1962a.WG04	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197143	505_1962a.WG05	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197141	505_1962a.WG06	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197139	505_1962a.WG07	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197145	505_1962a.WG08	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197140	505_1962a.WG10	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197138	505_1962a.WG11	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197144	505_1962a.WG12	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197142	505_1962a.WG13	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 352101;participant 505-1962;subtype: B	1	231	6L,15L,31S,83L,87Q,91V,95H,96L,98D,116A,120H,124V,180D,191I,205M,208G,210S,225S
MG197148	505_1982a.WG04	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,40FL,83L,86P,87Q,96I,110N,116T
MG197147	505_1982a.WG06	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197146	505_1982a.WG07	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197152	505_1982a.WG08	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197150	505_1982a.WG09	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197154	505_1982a.WG10	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197153	505_1982a.WG11	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197151	505_1982a.WG12	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197155	505_1982a.WG13	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197149	505_1982a.WG14	USA	2011		genomic RNA	plasma	treatment = vaccine; viral-load = 41055;participant 505-1982;subtype: B	1	231	6L,83L,86P,87Q,96I,110N,116T
MG197158	505_1993a.LH01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197162	505_1993a.LH02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197157	505_1993a.LH03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197161	505_1993a.LH04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197159	505_1993a.LH06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197163	505_1993a.LH07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197156	505_1993a.LH08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 6328;participant 505-1993;subtype: B	1	231	6L,14P,79D,83L,180D,194S,230I
MG197186	505_2150a.WG01	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197183	505_2150a.WG02	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197184	505_2150a.WG04	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197181	505_2150a.WG05	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120G,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197179	505_2150a.WG06	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197176	505_2150a.WG07	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197182	505_2150a.WG09	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197178	505_2150a.WG11	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197185	505_2150a.WG12	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197177	505_2150a.WG13	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36X,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197180	505_2150a.WG15	USA	2012		genomic RNA	plasma	treatment = placebo; viral-load = 211828;participant 505-2150;subtype: B	1	231	6L,27I,36I,41T,83L,87Q,91V,98D,120S,135V,148V,154K,177C,178T,199R,200N,205M,225S
MG197193	505_2227a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197189	505_2227a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197187	505_2227a.WG04	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197191	505_2227a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197192	505_2227a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197194	505_2227a.WG07	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197195	505_2227a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,93LP,116A,123A,148V,178T
MG197188	505_2227a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197196	505_2227a.WG12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197190	505_2227a.WG13	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 440902;participant 505-2227;subtype: B	1	231	6L,14P,27I,44A,83L,116A,123A,148V,178T
MG197206	505_2474a.WG01	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,30EK,83L,91A,116A,148V,178T,208G
MG197207	505_2474a.WG02	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197200	505_2474a.WG03	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197208	505_2474a.WG05	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197199	505_2474a.WG06	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197201	505_2474a.WG08	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197203	505_2474a.WG09	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197209	505_2474a.WG10	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197205	505_2474a.WG11	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,20LS,27I,83L,91A,116A,148V,178T,208G
MG197198	505_2474a.WG12	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197204	505_2474a.WG13	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197202	505_2474a.WG14	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197197	505_2474a.WG15	USA	2012		genomic RNA	plasma	treatment = vaccine; viral-load = 32074;participant 505-2474;subtype: B	1	231	6L,15L,27I,83L,91A,116A,148V,178T,208G
MG197219	505_2483a.WG02	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,112P,120S,124V,148V,178T,230I
MG197210	505_2483a.WG03	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,120S,124V,148V,178T,230I
MG197211	505_2483a.WG04	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,116A,120S,124V,148V,178T,230I
MG197214	505_2483a.WG05	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,120S,124V,148V,178T,230I
MG197212	505_2483a.WG06	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,110N,120S,124V,148V,178T,230I
MG197215	505_2483a.WG09	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,110N,120S,124V,148V,178T,230I
MG197213	505_2483a.WG11	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,110N,120S,124V,148V,178T,230I
MG197216	505_2483a.WG12	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,111P,120S,124V,148V,178T,230I
MG197217	505_2483a.WG13	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,30EK,83L,91P,96L,110N,120S,124V,148V,178T,230I
MG197218	505_2483a.WG14	USA	2010		genomic RNA	plasma	treatment = placebo; viral-load = 27847;participant 505-2483;subtype: B	1	231	6L,16T,27I,83L,91P,96L,110N,120S,124V,148V,178T,230I